2024 | Frontier Medicines

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

August 27, 2025/in 2024, Press Release/by eallison

July 23, 2024

Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension

August 27, 2025/in 2024, Press Release/by eallison

June 25, 2024

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

August 27, 2025/in 2024, Press Release/by eallison

April 9, 2024

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

August 27, 2025/in 2024, Press Release/by eallison

March 21, 2024

Frontier Medicines to Participate in Upcoming Investor Conferences

August 27, 2025/in 2024, Press Release/by eallison

February 27, 2024

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

August 27, 2025/in 2024, Press Release/by eallison

February 22, 2024

Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference

August 27, 2025/in 2024, Press Release/by eallison

January 3, 2024

Fierce Biotech: AACR: Verastem, Quanta and Frontier demonstrate KRAS inhibitors’ potential in preclinical data

August 19, 2025/in 2024, Media Coverage/by eallison

Fierce Biotech: Frontier CEO weathers ‘one of the hardest financings’ of his career to close $80M series C

August 19, 2025/in 2024, Media Coverage/by eallison

San Francisco Business Times: Peninsula biotech raises $80M as it doses 1st person in 1st clinical trial

August 19, 2025/in 2024, Media Coverage/by eallison